Loading organizations...
Servier Symphogen is the Antibody Center of Excellence in the Servier Group, focused on oncology and immune oncology, advancing antibody therapeutics.
Symphogen has raised $25.0M across 1 funding round.
Symphogen has raised $25.0M in total across 1 funding round.
Symphogen has raised $25.0M in total across 1 funding round.
Symphogen's investors include ALSA Ventures.
Symphogen is a Danish biotechnology company specializing in the discovery and development of recombinant antibody therapies primarily for oncology and immuno-oncology. It builds complex monoclonal antibody (mAb) mixtures designed to treat difficult cancers, aiming to deliver novel, highly differentiated antibodies either as standalone treatments or in combination therapies. Symphogen serves pharmaceutical companies and ultimately cancer patients by addressing the challenge of developing effective antibody-based cancer treatments with unique functionalities and best-in-class potential. Since its acquisition by the Servier Group in 2020, Symphogen operates as Servier’s Antibody Center of Excellence, supporting early-stage research through to clinical development, thus contributing significantly to Servier’s oncology R&D pipeline[1][2][3].
Symphogen was founded in Denmark with a focus on pioneering recombinant antibody mixtures for therapeutic use in cancer. The company’s founders and early team brought expertise in antibody technology and oncology drug development. The idea emerged from the need to improve cancer treatment efficacy by using complex antibody mixtures rather than single antibodies, which can better target tumors and overcome resistance. Early traction included strategic collaborations, notably a multi-year immuno-oncology partnership with Servier, which culminated in Servier’s acquisition of Symphogen in 2020. This acquisition validated Symphogen’s technology and portfolio strength, enabling it to continue as a standalone entity within Servier while expanding its impact in oncology[2][4].
Symphogen rides the growing trend of precision oncology and immuno-oncology, where antibody-based therapies are central to advancing cancer treatment. The timing is critical as the oncology field increasingly embraces combination therapies and complex biologics to improve patient outcomes. Market forces such as rising cancer incidence, demand for targeted therapies, and regulatory encouragement for innovative biologics favor Symphogen’s approach. By advancing complex antibody mixtures, Symphogen influences the broader biotech ecosystem by pushing the boundaries of antibody engineering and therapeutic development, setting new standards for efficacy and safety in cancer immunotherapy[1][3].
Looking ahead, Symphogen is poised to deepen its impact in oncology by advancing its antibody pipeline and expanding combination therapy options. Trends shaping its journey include the increasing integration of advanced analytics in biologics development, personalized medicine, and the growing importance of immuno-oncology. As cancer treatment paradigms evolve, Symphogen’s role as a center of excellence within Servier positions it to leverage innovation and scale its technologies globally. Its influence is likely to grow as it continues to deliver differentiated antibody therapies that address unmet needs in cancer care, reinforcing its strategic importance in the biotech and pharmaceutical landscape[2][3][5].
Symphogen has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series D in January 2006.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2006 | $25M Series D | — | ALSA Ventures | Announced |
